drugset / Trial / NCT05620771
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
RandomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this research is to compare progression free survival between two available systemic therapies - immunotherapy and tyrosine kinase inhibitors - after Therasphere® (yttrium-90) treatment in adult patients with advanced hepatocellular carcinoma. The immunotherapy consists of a standard-of-care treatment with Atezolizumab and Bevacizumab. Treatment with tyrosine kinase inhibitors consists of standard-of-care Lenvatinib or Cabozantinib.
Timeline
- Start
- 2022-11-30
- Primary completion
- 2040-07-01
- Completion
- 2040-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | — | — |
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Cabozantinib | Small molecule | — | — |
| Subject | Durvalumumab | Unknown | — | — |
| Subject | Lenvatinib | Small molecule | — | — |
| Subject | Tremelimumab | Monoclonal antibody | — | — |
| Background | Yttrium-90 | Other / unclassified | — | — |